Inactive Instrument

Eleven Biotherapeutics Inc Stock Nasdaq

US2862211065

Valuation: Eleven Biotherapeutics Inc

Market Cap	1.8M 1.58M 1.49M 1.36M 2.55M 173M 2.57M 17.9M 6.94M 87.91M 6.76M 6.61M 286M	P/E 2023	-1.13x	P/E 2024	-0.29x
Enterprise Value	-14.55M -12.8M -12.07M -11.01M -20.59M -1.4B -20.75M -145M -56.12M -711M -54.64M -53.46M -2.31B	EV / Sales 2023	2,933,403x	EV / Sales 2024	57,658x
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news: Eleven Biotherapeutics Inc

05-21	United Immunity, Co., Ltd. acquired Certain Macrophage Assets of Carisma Therapeutics Inc. from Carisma Therapeutics, Inc.	CI
03-05	Liberate Bio Secures Exclusive and Non-Exclusive Licenses to Myeloid-Optimized Car Design Patents from Carisma Therapeutics and the University of Pennsylvania	CI
02-04	Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor	CI
11-13	Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
16/10/25	Carisma Therapeutics - CEO Steven Kelly to leave effective November 15 - SEC filing	RE
16/10/25	Carisma Therapeutics, Inc. Announces Termination of Steven Kelly as Chief Executive Officer, Effective November 15, 2025	CI
16/10/25	Carisma Therapeutics, Inc. Announces Management Resignations	CI
15/10/25	Carisma Therapeutics, Inc.(NasdaqCM:CARM) dropped from S&P TMI Index	CI
10/10/25	Carisma Therapeutics, Inc.(OTCPK:CARM) dropped from NASDAQ Composite Index	CI
18/09/25	Carisma Therapeutics & Modernatx amend collaboration and license agreement - SEC filing	RE
16/09/25	OrthoCellix cancelled the acquisition of Carisma Therapeutics, Inc. from group of shareholders in a reverse merger transaction.	CI
08/08/25	Carisma Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
23/06/25	OrthoCellix, Inc. entered into an agreement to Carisma Therapeutics, Inc. in a reverse merger transaction.	CI

More news

Analysts' recommendations: Eleven Biotherapeutics Inc

16/12/24	HC Wainwright Downgrades Carisma Therapeutics to Neutral From Buy	MT
12/12/24	Baird Downgrades Carisma Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $10	MT
10/12/24	BTIG Downgrades Carisma Therapeutics to Neutral From Buy	MT
11/04/24	BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target	MT
02/04/24	HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating	MT

More recommendations

Press Releases: Eleven Biotherapeutics Inc

12-05	Carisma Announces Delisting from Nasdaq and SEC Deregistration	PR
01/04/25	Carisma Therapeutics Provides Corporate Updates	PR
19/02/25	Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference	PR
05/02/25	Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference	PR
27/11/24	Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference	PR

More press releases

News in other languages: Eleven Biotherapeutics Inc

02/01/23	MORNING BRIEFING - USA/Asien
02/01/23	MORNING BRIEFING - Deutschland/Europa
31/12/22	MÄRKTE USA/Wall Street beendet schwaches Börsenjahr knapp behauptet
30/12/22	MÄRKTE USA/Leichter - Schwächstes Börsenjahr seit 2008
30/12/22	MÄRKTE USA/Schwächer - Anleihen mit historisch schlechtem Jahr

More news

Sesen Bio, Inc. is a late-stage clinical company engaged in advancing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company's advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).

Employees

Sector

More about the company

	2023	2024
Net sales	14.92 13.12 12.37 11.29 21.11 1.43K 21.27 148.45 57.53 728.86 56.01 54.8 2.37K	19.63 17.27 16.28 14.85 27.77 1.88K 27.99 195.35 75.7 959.12 73.71 72.11 3.12K
Net income	-86.88M -76.42M -72.04M -65.73M -123M -8.34B -124M -864M -335M -4.24B -326M -319M -13.81B	-60.48M -53.2M -50.15M -45.75M -85.56M -5.81B -86.23M -602M -233M -2.95B -227M -222M -9.61B
Net Debt	-74.48M -65.51M -61.76M -56.35M -105M -7.15B -106M -741M -287M -3.64B -280M -274M -11.84B	-16.35M -14.38M -13.56M -12.37M -23.14M -1.57B -23.32M -163M -63.06M -799M -61.4M -60.07M -2.6B

Eleven Biotherapeutics Inc Stock Nasdaq

Stocks

US2862211065

Valuation: Eleven Biotherapeutics Inc

Latest news: Eleven Biotherapeutics Inc

Analysts' recommendations: Eleven Biotherapeutics Inc

Press Releases: Eleven Biotherapeutics Inc

News in other languages: Eleven Biotherapeutics Inc

Quotes and Performance

Financials

Company Profile